Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Licenses Gene-Delivery Technology from Cell Genesys

NEW YORK, Aug. 10 – Invitrogen has exclusively licensed lentiviral gene-delivery technology from Cell Genesys for use in gene-expression research and drug-target validation, the companies said on Friday. 

The agreement grants San Diego-based Invitrogen worldwide rights to sell kits, products, and services using the lentiviral-vector technology. In return, Invitrogen will pay Cell Genesys royalties on any sales, as well as a portion of fees generated from sublicensing the technology to companies applying the technology to commercial bioprocessing or in their own products.

Lentiviral gene delivery is one technique for modifying a cell or organism’s DNA by delivering genetic information directly into a cell’s nucleus. The method is particularly useful for gene expression and drug-target validation studies in non-dividing or slowly dividing cells, the companies said in a statement.

Cell Genesys, based in Foster City, Calif., is developing cancer vaccines and gene-therapy techniques for treating major diseases. For applications outside of this focus, the company is seeking partners to license its gene-delivery intellectual property.

Last week, Cell Genesys acquired Calydon, a Sunnyvale, Calif.-based biotechnology company focused on developing therapeutic products for cancer. Cell Genesys also holds a 10.5 percent stake in antibody manufacturer Abgenix, based in Fremont, Calif.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.